Developer docs
API playgroundTry for free, no card

Search company profiles

Odyssey Therapeutics

Full company profile

uuid000008o

Namestring
Odyssey Therapeutics
Legal namestring
Odyssey Therapeutics, Inc.
Websiteurl
odysseytx.com
Company typeenum
Public
Founded yearint
2021
Descriptiontext

Odyssey Therapeutics is a Boston-based, publicly traded clinical-stage biopharmaceutical company (Nasdaq: ODTX, IPO May 2026) founded in 2021 by Gary D. Glick, focused on developing precision immunomodulators and protein therapeutics for patients with autoimmune and inflammatory diseases. The company's scientific thesis targets upstream signaling nodes in the innate immune system — notably scaffolding inhibition of RIPK2 (OD-001) and IRAK4, SLC15A4/TASL blockade (OD-002) and selective TNFR2 agonism (OD-003) — to address cytokine redundancy that limits current downstream cytokine blockers. The pipeline comprises eight declared programs spanning ulcerative colitis, Crohn's disease, lupus, atopic dermatitis, asthma, COPD and additional B cell-mediated and dermatologic indications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
immunomodulatory therapeutics, autoimmune disease drugs, clinical-stage biopharmaceutical, precision oncology medicines, innate immune therapeutics
Industry3 codes
PRIMARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Computer Systems Design and Related Services54151
SIC code1 code
  • Services-Misc Health & Allied Services, Nec8090
Product category
Immunology Therapeutics
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pre-revenue clinical-stage biotech
TypeSubscription Recurring
Description

Odyssey is a clinical-stage biopharmaceutical company with no approved products and no product revenue; reported a 33.5% year-over-year revenue decline and net loss of $148.6 million in 2025, with operating losses of $157.1 million. Future revenue expected from commercialization of internally-discovered small molecule and protein therapeutics for autoimmune and inflammatory diseases.

tradingview.com
2Future pharmaceutical product sales
TypeOne Time License
Description

Management aims to build a 'little large pharma' and potentially pursue commercialization independently rather than relying on early acquisition deals, indicating intent to capture downstream product revenue across autoimmune and inflammatory indications.

fiercebiotech.com
3Potential collaboration and licensing revenue
TypeLicensing Royalties
Description

Strategic collaborations with partners such as Takeda (Entyvio combination), Johnson & Johnson, Terray, and Spark Biopharma suggest future potential for collaboration, licensing, milestone, or royalty-based revenue streams.

linkedin.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1OD-001
Description

Oral small molecule RIPK2 scaffolding inhibitor; lead product candidate in Phase 2 for ulcerative colitis and Crohn's disease.

odysseytx.com
+2 more records
Core offering1 text field

Odyssey Therapeutics is a clinical-stage biopharmaceutical company developing precision immunomodulators and oncology medicines that target upstream signaling nodes in the innate immune system to treat autoimmune and inflammatory diseases. Its pipeline consists of small molecule and protein therapeutic candidates — including the lead RIPK2 scaffolding inhibitor OD-001 (Phase 2a in ulcerative colitis), the SLC15A4 inhibitor OD-002, the TNFR2 agonist OD-003, a TSLP/IL-33 bispecific antagonist, an IRAK4 scaffolding inhibitor and an IRF5 inhibitor — supported by a proprietary AI/ML drug discovery platform enhanced by quantum machine learning from the acquired company Rahko.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 27% clinical remission and 61% clinical response in Phase 2a monotherapy trial of OD-001 in moderate to severe ulcerative colitis
+2 more records
Product overview1 text field

Odyssey Therapeutics operates a single clinical-stage biopharmaceutical platform focused on discovering, developing, and commercializing precision medicines for autoimmune and inflammatory diseases. Its portfolio is unified around a strategy of targeting upstream signaling nodes in the innate immune system to prevent pathological inflammation. The core offerings include clinical-stage small molecule candidates OD-001 (RIPK2 scaffolding inhibitor) and OD-002 (SLC15A4 inhibitor), protein therapeutic OD-003 (TNFR2 agonist), and earlier-stage programs including a TSLP/IL-33 bispecific antagonist, an IRAK4 scaffolding inhibitor, and an IRF5 inhibitor (in collaboration with Terray). These candidates are supported by Odyssey's proprietary AI/ML drug discovery platform, which integrates medicinal and computational chemistry, structural biology, genetics, and pharmacology to accelerate the identification and development of novel therapeutics.

Product and service6 records
1OD-001 (RIPK2 Scaffolding Inhibitor)
CategoryClinical-stage product candidate (small molecule)
Description

Oral small molecule RIPK2 scaffolding inhibitor designed to block downstream pathway signaling and activation of pro-inflammatory cells of both innate and adaptive immune systems by blocking multiple validated cytokines (TNF, TL1A, IL-23); in development for ulcerative colitis and Crohn's disease.

2OD-002 (SLC15A4 Inhibitor)
CategoryClinical-stage product candidate (small molecule)
Description

Oral small molecule designed to selectively block TLR7/8/9-mediated activation of IRF5 via SLC15A4, intended as a first-in-class approach to block disease-relevant signaling while retaining other host defense functions of IRF5; targets lupus and B cell-mediated diseases.

3OD-003 (TNFR2 Agonist)
CategoryProduct candidate (protein therapeutic)
Description

Protein therapeutic designed to selectively agonize TNFR2 on Treg cells to increase Treg number, improve immunosuppressive function and tissue homing, and enable stable immunosuppressive phenotype; addresses shortcomings of IL-2 approaches.

4TSLP/IL-33 Bispecific Antagonist
CategoryProduct candidate (protein therapeutic)
Description

Bispecific antagonist designed to address upstream cytokine redundancy and improve suppression of inflammation in asthma and COPD by targeting two alarmins (TSLP and IL-33) with redundant function.

5IRAK4 Scaffolding Inhibitor
CategoryProduct candidate (small molecule)
Description

Oral small molecule scaffolding inhibitor designed to block inflammatory signaling by the myddosome, addressing shortcomings of kinase inhibitors and degraders by achieving desired pharmacology to block cytokine production across disease-relevant cell types.

6IRF5 Inhibitor (Terray collaboration)
CategoryCollaborative product candidate (small molecule)
Description

Small molecule inhibitor of IRF5 being co-developed with Terray Therapeutics as a complementary strategy to Odyssey's wholly owned SLC15A4 inhibitor for targeting the interferon pathway across different diseases.

Scale indicator20 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Combination clinical collaboration: Odyssey's lead RIPK2 inhibitor OD-001 is being tested in combination with Takeda's marketed Entyvio (vedolizumab) in a Phase 2a trial for ulcerative colitis (per the Odyssey CEO commentary). $135 million of IPO proceeds earmarked for the OD-001 monotherapy and Entyvio combination Phase 2 trials.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Reported as a collaboration partner on Odyssey's pipeline of autoimmune disease treatments (mentioned alongside Terray Therapeutics in coverage of the September 2025 Series D round).

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration to develop a small molecule inhibitor of IRF5; IRF5 inhibition is positioned as a complementary strategy to Odyssey's wholly owned SLC15A4 inhibitor for targeting the interferon pathway across different diseases.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration to develop autoimmune and inflammatory disease drugs using Spark's pDOS technology within Odyssey's research strategy; intended to diversify Odyssey's development pipeline.

Strategic tierCoreTypeTechnology or Integration
Description

Acquisition (January 2022) of London-based machine learning company Rahko to accelerate drug discovery through quantum machine learning technology; several Odyssey programs in lead optimization stages reportedly leveraged Rahko's capabilities.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage immunology company developing biologics for atopic dermatitis, asthma, COPD, and other inflammatory diseases. Closely comparable in stage, indication focus, and modality mix to Odyssey's pipeline.

2Prometheus Biosciences
TypeDirect peer
Description

Clinical-stage IBD and immunology company acquired by Merck for ~$10.8B in 2023. Directly comparable to Odyssey's RIPK2/IBD strategy and serves as a key recent precedent for valuation of late-clinical-stage autoimmune biotechs.

3Morphic Holding
TypeDirect peer
Description

Clinical-stage oral small molecule company developing integrin inhibitors for autoimmune diseases (IBD, fibrosis). Acquired by Eli Lilly for ~$3.2B in 2024; a direct comp for Odyssey's oral small molecule immunology strategy.

4Dice Therapeutics
TypeDirect peer
Description

Clinical-stage company developing oral IL-17 small molecule inhibitors for psoriasis and other autoimmune diseases; acquired by Eli Lilly for ~$2.4B in 2023. Comparable to Odyssey in modality (oral small molecules) and immunology focus.

TypeDirect peer
Description

Clinical-stage immunology company developing nanobody-based therapies (sonelokimab) for inflammatory skin and joint diseases. Comparable in clinical stage, indication focus, and capital intensity to Odyssey.

TypeDirect peer
Description

Clinical-stage immunology company developing monoclonal antibodies for inflammatory diseases (e.g., izokibep for psoriatic arthritis/hidradenitis suppurativa). Directly comparable in stage, immunology focus, and biotech scale.

TypeDirect peer
Description

Clinical-stage small molecule company developing integrin-based therapies for fibrotic and inflammatory diseases. Comparable in clinical stage, small molecule modality, and chronic inflammatory disease focus.

TypeBroad incumbent
Description

Global pharmaceutical leader with dominant autoimmune franchises (Humira, Skyrizi, Rinvoq) across IBD, dermatology, and rheumatology. Sets the competitive baseline Odyssey must beat in target indications.

9Bristol Myers Squibb
TypeBroad incumbent
Description

Large pharmaceutical company with significant immunology franchise (Zeposia, Sotyktu) in IBD, psoriasis, and lupus. Competes in the same autoimmune indications Odyssey is targeting.

TypeBroad incumbent
Description

Global pharmaceutical company and Odyssey's combination trial partner for OD-001 + Entyvio. Competes directly in IBD and immunology and represents a potential strategic commercialization partner or acquirer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles23 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors30 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Odyssey Therapeutics

Immunology Therapeuticsodysseytx.com

What Odyssey Therapeutics does

Odyssey Therapeutics is a Boston-based, publicly traded clinical-stage biopharmaceutical company (Nasdaq: ODTX, IPO May 2026) founded in 2021 by Gary D. Glick, focused on developing precision immunomodulators and protein therapeutics for patients with autoimmune and inflammatory diseases. The company's scientific thesis targets upstream signaling nodes in the innate immune system — notably scaffolding inhibition of RIPK2 (OD-001) and IRAK4, SLC15A4/TASL blockade (OD-002) and selective TNFR2 agonism (OD-003) — to address cytokine redundancy that limits current downstream cytokine blockers. The pipeline comprises eight declared programs spanning ulcerative colitis, Crohn's disease, lupus, atopic dermatitis, asthma, COPD and additional B cell-mediated and dermatologic indications.

Odyssey Therapeutics firmographics

Firmographics
Name
Odyssey Therapeutics
Legal name
Odyssey Therapeutics, Inc.
Website
https://odysseytx.com
Company type
Public
Founded year
2021
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

Odyssey Therapeutics industry classification

Industry
Product category
Immunology Therapeutics
NAICS
Computer Systems Design and Related Services (54151)
SIC
Services-Misc Health & Allied Services, Nec (8090)
akta.pro industry
PRIMARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Immunomodulatory therapeutics
  • Autoimmune disease drugs
  • Clinical-stage biopharmaceutical
  • Precision oncology medicines
  • Innate immune therapeutics

Where Odyssey Therapeutics is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Odyssey Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure

Revenue model

  1. Pre-revenue clinical-stage biotech: Odyssey is a clinical-stage biopharmaceutical company with no approved products and no product revenue; reported a 33.5% year-over-year revenue decline and net loss of $148.6 million in 2025, with operating losses of $157.1 million. Future revenue expected from commercialization of internally-discovered small molecule and protein therapeutics for autoimmune and inflammatory diseases.
  2. Future pharmaceutical product sales: Management aims to build a 'little large pharma' and potentially pursue commercialization independently rather than relying on early acquisition deals, indicating intent to capture downstream product revenue across autoimmune and inflammatory indications.
  3. Potential collaboration and licensing revenue: Strategic collaborations with partners such as Takeda (Entyvio combination), Johnson & Johnson, Terray, and Spark Biopharma suggest future potential for collaboration, licensing, milestone, or royalty-based revenue streams.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels7 records

Odyssey Therapeutics product offering

Product offering

Core offering

Odyssey Therapeutics is a clinical-stage biopharmaceutical company developing precision immunomodulators and oncology medicines that target upstream signaling nodes in the innate immune system to treat autoimmune and inflammatory diseases. Its pipeline consists of small molecule and protein therapeutic candidates — including the lead RIPK2 scaffolding inhibitor OD-001 (Phase 2a in ulcerative colitis), the SLC15A4 inhibitor OD-002, the TNFR2 agonist OD-003, a TSLP/IL-33 bispecific antagonist, an IRAK4 scaffolding inhibitor and an IRF5 inhibitor — supported by a proprietary AI/ML drug discovery platform enhanced by quantum machine learning from the acquired company Rahko.

Product overview

Odyssey Therapeutics operates a single clinical-stage biopharmaceutical platform focused on discovering, developing, and commercializing precision medicines for autoimmune and inflammatory diseases. Its portfolio is unified around a strategy of targeting upstream signaling nodes in the innate immune system to prevent pathological inflammation. The core offerings include clinical-stage small molecule candidates OD-001 (RIPK2 scaffolding inhibitor) and OD-002 (SLC15A4 inhibitor), protein therapeutic OD-003 (TNFR2 agonist), and earlier-stage programs including a TSLP/IL-33 bispecific antagonist, an IRAK4 scaffolding inhibitor, and an IRF5 inhibitor (in collaboration with Terray). These candidates are supported by Odyssey's proprietary AI/ML drug discovery platform, which integrates medicinal and computational chemistry, structural biology, genetics, and pharmacology to accelerate the identification and development of novel therapeutics.

Differentiator

Problem solved

Functional benefit

Brands

  • OD-001: Oral small molecule RIPK2 scaffolding inhibitor; lead product candidate in Phase 2 for ulcerative colitis and Crohn's disease.
  • OD-002
  • OD-003

Products and services

  • OD-001 (RIPK2 Scaffolding Inhibitor) Oral small molecule RIPK2 scaffolding inhibitor designed to block downstream pathway signaling and activation of pro-inflammatory cells of both innate and adaptive immune systems by blocking multiple validated cytokines (TNF, TL1A, IL-23); in development for ulcerative colitis and Crohn's disease.
  • OD-002 (SLC15A4 Inhibitor) Oral small molecule designed to selectively block TLR7/8/9-mediated activation of IRF5 via SLC15A4, intended as a first-in-class approach to block disease-relevant signaling while retaining other host defense functions of IRF5; targets lupus and B cell-mediated diseases.
  • OD-003 (TNFR2 Agonist) Protein therapeutic designed to selectively agonize TNFR2 on Treg cells to increase Treg number, improve immunosuppressive function and tissue homing, and enable stable immunosuppressive phenotype; addresses shortcomings of IL-2 approaches.
  • TSLP/IL-33 Bispecific Antagonist Bispecific antagonist designed to address upstream cytokine redundancy and improve suppression of inflammation in asthma and COPD by targeting two alarmins (TSLP and IL-33) with redundant function.
  • IRAK4 Scaffolding Inhibitor Oral small molecule scaffolding inhibitor designed to block inflammatory signaling by the myddosome, addressing shortcomings of kinase inhibitors and degraders by achieving desired pharmacology to block cytokine production across disease-relevant cell types.
  • IRF5 Inhibitor (Terray collaboration) Small molecule inhibitor of IRF5 being co-developed with Terray Therapeutics as a complementary strategy to Odyssey's wholly owned SLC15A4 inhibitor for targeting the interferon pathway across different diseases.

Quantifiable outcome

  • 27% clinical remission and 61% clinical response in Phase 2a monotherapy trial of OD-001 in moderate to severe ulcerative colitis
  • +2 more outcomes

Companies that use Odyssey Therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

Odyssey Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature7 records

Odyssey Therapeutics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • Takeda Pharmaceutical Company LimitedcoreStrategic or Co-development PartnerCombination clinical collaboration: Odyssey's lead RIPK2 inhibitor OD-001 is being tested in combination with Takeda's marketed Entyvio (vedolizumab) in a Phase 2a trial for ulcerative colitis (per the Odyssey CEO commentary). $135 million of IPO proceeds earmarked for the OD-001 monotherapy and Entyvio combination Phase 2 trials.
  • Johnson & JohnsoncoreStrategic or Co-development PartnerReported as a collaboration partner on Odyssey's pipeline of autoimmune disease treatments (mentioned alongside Terray Therapeutics in coverage of the September 2025 Series D round).
  • Terray TherapeuticscoreStrategic or Co-development PartnerCollaboration to develop a small molecule inhibitor of IRF5; IRF5 inhibition is positioned as a complementary strategy to Odyssey's wholly owned SLC15A4 inhibitor for targeting the interferon pathway across different diseases.
  • Spark BiopharmacoreStrategic or Co-development PartnerCollaboration to develop autoimmune and inflammatory disease drugs using Spark's pDOS technology within Odyssey's research strategy; intended to diversify Odyssey's development pipeline.
  • RahkocoreTechnology or IntegrationAcquisition (January 2022) of London-based machine learning company Rahko to accelerate drug discovery through quantum machine learning technology; several Odyssey programs in lead optimization stages reportedly leveraged Rahko's capabilities.

Scale indicators20 records

Recent moves7 records

Expansion highlights6 records

Odyssey Therapeutics competitors and assessment

Company assessment

Direct peers

  • Apogee Therapeutics: Clinical-stage immunology company developing biologics for atopic dermatitis, asthma, COPD, and other inflammatory diseases. Closely comparable in stage, indication focus, and modality mix to Odyssey's pipeline.
  • Prometheus Biosciences: Clinical-stage IBD and immunology company acquired by Merck for ~$10.8B in 2023. Directly comparable to Odyssey's RIPK2/IBD strategy and serves as a key recent precedent for valuation of late-clinical-stage autoimmune biotechs.
  • Morphic Holding: Clinical-stage oral small molecule company developing integrin inhibitors for autoimmune diseases (IBD, fibrosis). Acquired by Eli Lilly for ~$3.2B in 2024; a direct comp for Odyssey's oral small molecule immunology strategy.
  • Dice Therapeutics: Clinical-stage company developing oral IL-17 small molecule inhibitors for psoriasis and other autoimmune diseases; acquired by Eli Lilly for ~$2.4B in 2023. Comparable to Odyssey in modality (oral small molecules) and immunology focus.
  • MoonLake Immunotherapeutics: Clinical-stage immunology company developing nanobody-based therapies (sonelokimab) for inflammatory skin and joint diseases. Comparable in clinical stage, indication focus, and capital intensity to Odyssey.
  • Acelyrin: Clinical-stage immunology company developing monoclonal antibodies for inflammatory diseases (e.g., izokibep for psoriatic arthritis/hidradenitis suppurativa). Directly comparable in stage, immunology focus, and biotech scale.
  • Pliant Therapeutics: Clinical-stage small molecule company developing integrin-based therapies for fibrotic and inflammatory diseases. Comparable in clinical stage, small molecule modality, and chronic inflammatory disease focus.

Broad incumbents

  • AbbVie: Global pharmaceutical leader with dominant autoimmune franchises (Humira, Skyrizi, Rinvoq) across IBD, dermatology, and rheumatology. Sets the competitive baseline Odyssey must beat in target indications.
  • Bristol Myers Squibb: Large pharmaceutical company with significant immunology franchise (Zeposia, Sotyktu) in IBD, psoriasis, and lupus. Competes in the same autoimmune indications Odyssey is targeting.
  • Takeda Pharmaceutical: Global pharmaceutical company and Odyssey's combination trial partner for OD-001 + Entyvio. Competes directly in IBD and immunology and represents a potential strategic commercialization partner or acquirer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Odyssey Therapeutics social profiles

Digital presence

Odyssey Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Odyssey Therapeutics leadership team

Management profile

Number of profiles

Profiles23 records

Odyssey Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Odyssey Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors30 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Odyssey Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Odyssey Therapeutics

What does Odyssey Therapeutics do?

Odyssey Therapeutics is a clinical-stage biopharmaceutical company developing precision immunomodulators and oncology medicines that target upstream signaling nodes in the innate immune system to treat autoimmune and inflammatory diseases. Its pipeline consists of small molecule and protein therapeutic candidates — including the lead RIPK2 scaffolding inhibitor OD-001 (Phase 2a in ulcerative colitis), the SLC15A4 inhibitor OD-002, the TNFR2 agonist OD-003, a TSLP/IL-33 bispecific antagonist, an IRAK4 scaffolding inhibitor and an IRF5 inhibitor — supported by a proprietary AI/ML drug discovery platform enhanced by quantum machine learning from the acquired company Rahko.

Is Odyssey Therapeutics a public or private company?

Odyssey Therapeutics is a public company. It is classified as public and is currently operating.

When was Odyssey Therapeutics founded?

Odyssey Therapeutics was founded in 2021. It employs 101 to 250 people.

Where is Odyssey Therapeutics based?

Odyssey Therapeutics is headquartered in Boston, United States, in the North America region.

How does Odyssey Therapeutics make money?

Three revenue lines are on record. Pre-revenue clinical-stage biotech is the primary driver. The others are future pharmaceutical product sales and potential collaboration and licensing revenue.

Who are Odyssey Therapeutics's main competitors?

Direct peers on record are Apogee Therapeutics, Prometheus Biosciences, Morphic Holding, Dice Therapeutics, MoonLake Immunotherapeutics, Acelyrin and Pliant Therapeutics. Broad incumbents are AbbVie, Bristol Myers Squibb and Takeda Pharmaceutical.

Does Odyssey Therapeutics have an API?

No public API is recorded for Odyssey Therapeutics.

What industry is Odyssey Therapeutics in?

Odyssey Therapeutics's product category is Immunology Therapeutics. Its primary akta.pro industry code is HLAAAAAJ, Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 54151 and its SIC code is 8090.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Stock TitanOdyssey Therapeutics publishes TNFR2 studyOdyssey Therapeutics published a study in The Journal of Immunology showing TNFR2 agonism expands tissue-directed regulatory T cells in mice, increasing a subset from 22% to 66% after a single dose. The company's investigational TNFR2 agonist OD-003 is expected to complete IND-enabling studies in the first quarter of 2027.MarketBeatOdyssey Therapeutics, Inc. (NASDAQ:ODTX) Stock Has Consensus Price Target of $35.33Analysts rate Odyssey Therapeutics a Moderate Buy with an average 12-month price target of $35.33. The stock opened at $19.83, and the company reported a quarterly loss of $1.74 per share. Analysts forecast a fiscal-year EPS of -$6.08.American Banking and Market NewsOdyssey Therapeutics, Inc.’s Lock-Up Period Will Expire on November 4th (NASDAQ:ODTX)Odyssey Therapeutics' lock-up period ends November 4th, lifting restrictions on major shareholders and insiders. The company issued 15.5 million shares in a $279 million offering on May 8th. Analysts have a consensus 'Moderate Buy' rating with an average price target of $35.33.MarketBeatOdyssey Therapeutics Highlights OD-001 Phase IIa UC Data, Sets 2027 Trial ReadoutsOdyssey Therapeutics presented Phase IIa data for OD-001, an oral RIPK2 inhibitor for ulcerative colitis, showing 27% clinical remission at 20 mg twice daily. The company plans Phase IIb monotherapy and combination trials with vedolizumab, with readouts expected in 2027.Seeking AlphaOdyssey Therapeutics, Inc. (ODTX) Discusses Additional Phase IIa Data for OD-001 in Ulcerative Colitis from UEG Week Presentation TranscriptOdyssey Therapeutics CEO Gary Glick presented additional Phase IIa data for OD-001 in ulcerative colitis at UEG Week, including complete induction data, biomarkers, and mucosal transcriptomics. The data comes from an ongoing study, with no head-to-head comparisons and results subject to change.TradingViewOdyssey Therapeutics: Phase 2a OD-001 shows significant mMS improvement, 20 mg BID selected for Phase 2bOdyssey Therapeutics reported Phase 2a OD-001 induction results showing a mean modified Mayo score reduction of 2.4 points at Week 12 across 56 evaluable patients. The 20 mg BID dose achieved 27% clinical remission and 61% clinical response, with supportive biomarker and transcriptomic evidence, leading to its selection for Phase 2b.Ticker ReportOdyssey Therapeutics (NASDAQ:ODTX) Stock Rating Upgraded by UBS GroupUBS Group upgraded Odyssey Therapeutics to a strong-buy rating on Monday. The stock opened at $17.24, with an average analyst rating of Moderate Buy and a price target of $35.33. The company reported a loss of $1.74 per share for the quarter.MarketBeatOdyssey Therapeutics (NASDAQ:ODTX) Upgraded at UBS GroupUBS Group upgraded Odyssey Therapeutics to a "strong-buy" rating in a research report issued on Monday. The company also received various ratings from other firms including Oppenheimer, JPMorgan, and Raymond James, with an average target price of $35.33 among analysts. Additionally, several hedge funds such as Citadel Advisors LLC and State Street Corp increased their positions in the stock during the second quarter.MarketBeatOdyssey Therapeutics (NASDAQ:ODTX) Now Covered by Analysts at Raymond James FinancialRaymond James Financial initiated coverage on Odyssey Therapeutics with a moderate buy rating. The stock has an average analyst price target of $37.00, and shares opened at $19.00 on Thursday.Investing.comRaymond James initiates Odyssey Therapeutics stock coverage with outperform ratingRaymond James initiated coverage on Odyssey Therapeutics with an Outperform rating and a $42 price target, citing a compelling long-term risk/reward profile ahead of Phase 2 readouts. The stock trades at $18.12, down 11% over the past week but up 10% year-to-date. Phase 2 ulcerative colitis readouts for OD-001 are expected in the second half of 2027.